NCT05742087

Neuropathy and Anti-GFAP Antibodies

Study of the Consequences of Anti-GFAP Antibodies on the Peripheral Nervous System

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 120 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also expressed by immature and non-myelinating Schwann cells. Thus, these antibodies could also lead to damages of the peripheral nervous system (PNS). Moreover, such damages have already been reported on small studies, and there is a need for larger cohorts. The investigators will use the cohort of patients with neurological syndromes and anti-GFAP antibodies identified in the cerebrospinal fluid (CSF) of the "Reference center for paraneoplastic neurological syndromes and autoimmune encephalitis" to determine the frequency of the PNS involvement in these patients.

Conditions

• Neurological Diseases or Conditions
• Neurological Diseases Associated to Anti GFAP Antibodies

Interventions

Type	Name	Description
OTHER	Clinical examination	The examination performed by the clinician of the patient will be analyzed from the cohort as previously explained.
OTHER	electroneuromyography (ENMG)	Data from the ENMGs will be extracted from the cohort and analyzed.

Timeline

• Start date: 2022-09-01
• Primary completion: 2022-10-01
• Completion: 2023-05-01
• First posted: 2023-02-23
• Last updated: 2023-02-23

Locations

1 site across 1 country: France